StockData
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA) stock

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.73+0.01 (+0.58%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Processa Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Processa Pharmaceuticals's operating income for the twelve months ending Dec 31, 2025 was -$13.99M. For fiscal 2025 it was -$13.99M. The highest annual figure on record is -$1.80M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.99M–
FY2024Dec 31, 2024-$12.05M–
FY2023Dec 31, 2023-$11.46M–
FY2022Dec 31, 2022-$27.53M–
FY2021Dec 31, 2021-$12.13M–
FY2020Dec 31, 2020-$15.14M–
FY2019Dec 31, 2019-$3.94M–
FY2018Dec 31, 2018-$4.52M–
FY2017Dec 31, 2017-$1.80M–
FY2016Dec 31, 2016-$1.92M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.34M–
Q1 FY2026Mar 31, 2026-$3.33M–
Q4 FY2025Dec 31, 2025-$3.70M–
Q1 FY2025Mar 31, 2025-$2.85M–
Q4 FY2024Dec 31, 2024-$2.73M–
Q3 FY2024Sep 30, 2024-$3.42M–
Q2 FY2024Jun 30, 2024-$3.08M–
Q1 FY2024Mar 31, 2024-$2.81M–
Q4 FY2023Dec 31, 2023-$2.47M–
Q3 FY2023Sep 30, 2023-$2.17M–
Q2 FY2023Jun 30, 2023-$2.71M–
Q1 FY2023Mar 31, 2023-$4.11M–
Q4 FY2022Dec 31, 2022-$13.07M–
Q3 FY2022Sep 30, 2022-$6.06M–
Q2 FY2022Jun 30, 2022-$5.17M–
Q1 FY2022Mar 31, 2022-$3.23M–
Q4 FY2021Dec 31, 2021-$3.37M–
Q3 FY2021Sep 30, 2021-$3.11M–
Q2 FY2021Jun 30, 2021-$3.46M–
Q1 FY2021Mar 31, 2021-$2.19M–
Q4 FY2020Dec 31, 2020-$10.39M–
Q3 FY2020Sep 30, 2020-$2.96M–
Q2 FY2020Jun 30, 2020-$801.99K–
Q1 FY2020Mar 31, 2020-$986.12K–
Q4 FY2019Dec 31, 2019-$911.98K–
Q3 FY2019Sep 30, 2019-$1.00M–
Q2 FY2019Jun 30, 2019-$1.14M–
Q1 FY2019Mar 31, 2019-$882.52K–
Q4 FY2018Dec 31, 2018-$741.95K–
Q3 FY2018Sep 30, 2018-$1.06M–
Q2 FY2018Jun 30, 2018-$1.43M–
Q1 FY2018Mar 31, 2018-$1.29M–
Q4 FY2017Dec 31, 2017-$575.31K–
Q1 FY2017Mar 31, 2017-$233.94K–

More Processa Pharmaceuticals figures

See a number that looks wrong?